120 related articles for article (PubMed ID: 22067800)
1. Deterioration in cardiometabolic risk markers in obese women during depot medroxyprogesterone acetate use.
Segall-Gutierrez P; Xiang AH; Watanabe RM; Trigo E; Stanczyk FZ; Liu X; Jurow R; Buchanan TA
Contraception; 2012 Jan; 85(1):36-41. PubMed ID: 22067800
[TBL] [Abstract][Full Text] [Related]
2. Effect of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC) on serum androgen markers in normal-weight, obese, and extremely obese women.
Segall-Gutierrez P; Du J; Niu C; Ge M; Tilley I; Mizraji K; Stanczyk FZ
Contraception; 2012 Dec; 86(6):739-45. PubMed ID: 22959905
[TBL] [Abstract][Full Text] [Related]
3. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously.
Segall-Gutierrez P; Taylor D; Liu X; Stanzcyk F; Azen S; Mishell DR
Contraception; 2010 Jun; 81(6):487-95. PubMed ID: 20472115
[TBL] [Abstract][Full Text] [Related]
4. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
5. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes.
Westhoff C
J Reprod Med; 1996 May; 41(5 Suppl):401-6. PubMed ID: 8725702
[TBL] [Abstract][Full Text] [Related]
6. Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive.
Pantoja M; Medeiros T; Baccarin MC; Morais SS; Bahamondes L; Fernandes AM
Contraception; 2010 Feb; 81(2):107-11. PubMed ID: 20103446
[TBL] [Abstract][Full Text] [Related]
7. A pilot study examining short-term changes in bone mineral density among class 3 obese users of depot-medroxyprogesterone acetate.
Segall-Gutierrez P; Agarwal R; Ge M; Lopez C; Hernandez G; Stanczyk FZ
Eur J Contracept Reprod Health Care; 2013 Jun; 18(3):199-205. PubMed ID: 23530919
[TBL] [Abstract][Full Text] [Related]
8. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate.
Viola AS; Castro S; Bahamondes MV; Fernandes A; Viola CF; Bahamondes L
Contraception; 2011 Nov; 84(5):e31-7. PubMed ID: 22018135
[TBL] [Abstract][Full Text] [Related]
9. Insulin resistance parameters in users of the injectable contraceptive depot medroxyprogesterone acetate during one year of use.
Cursino K; Sider M; Pavin EJ; dos Santos Pde N; Bahamondes L; Zantut-Wittmann DE; Fernandes A
Eur J Contracept Reprod Health Care; 2016; 21(1):22-9. PubMed ID: 26140543
[TBL] [Abstract][Full Text] [Related]
10. Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women.
Lizarelli PM; Martins WP; Vieira CS; Soares GM; Franceschini SA; Ferriani RA; Patta MC
Contraception; 2009 Jan; 79(1):35-40. PubMed ID: 19041439
[TBL] [Abstract][Full Text] [Related]
11. From metabolic normality to cardiometabolic risk factors in subjects with obesity.
Bobbioni-Harsch E; Pataky Z; Makoundou V; Laville M; Disse E; Anderwald C; Konrad T; Golay A;
Obesity (Silver Spring); 2012 Oct; 20(10):2063-9. PubMed ID: 22421925
[TBL] [Abstract][Full Text] [Related]
12. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids.
Enk L; Landgren BM; Lindberg UB; Silfverstolpe G; Crona N
Horm Metab Res; 1992 Feb; 24(2):85-9. PubMed ID: 1533383
[TBL] [Abstract][Full Text] [Related]
13. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study.
Brito MB; Ferriani RA; Quintana SM; Yazlle ME; Silva de Sá MF; Vieira CS
Contraception; 2009 Dec; 80(6):519-26. PubMed ID: 19913145
[TBL] [Abstract][Full Text] [Related]
14. Weight, fat mass, and central distribution of fat increase when women use depot-medroxyprogesterone acetate for contraception.
Clark MK; Dillon JS; Sowers M; Nichols S
Int J Obes (Lond); 2005 Oct; 29(10):1252-8. PubMed ID: 15997247
[TBL] [Abstract][Full Text] [Related]
15. Effects of progestin-only long-acting contraception on metabolic markers in obese women.
Bender NM; Segall-Gutierrez P; Najera SO; Stanczyk FZ; Montoro M; Mishell DR
Contraception; 2013 Sep; 88(3):418-25. PubMed ID: 23410714
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate.
Clark MK; Sowers MR; Nichols S; Levy B
Fertil Steril; 2004 Dec; 82(6):1580-6. PubMed ID: 15589863
[TBL] [Abstract][Full Text] [Related]
17. [Factors relevant to newborn birth weight in pregnancy complicated with abnormal glucose metabolism].
Yang YD; Zhai GR; Yang HX
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):646-51. PubMed ID: 21092542
[TBL] [Abstract][Full Text] [Related]
18. Weight and body fat changes in postpartum depot-medroxyprogesterone acetate users.
Nyirati CM; Habash DL; Shaffer LE
Contraception; 2013 Jul; 88(1):169-76. PubMed ID: 23177262
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation.
Kaunitz AM; Miller PD; Rice VM; Ross D; McClung MR
Contraception; 2006 Aug; 74(2):90-9. PubMed ID: 16860045
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
